Stockreport

Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update [Yahoo! Finance]

Astria Therapeutics, Inc.  (ATXS) 
PDF -- Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned with Topline Results Anticipated in Early 2027; First Patient Now Enrolled in the ORBIT-EXPANSE Lo [Read more]